Skip redundant pieces
University of Kansas Cancer Center
University of Kansas Cancer Center  :  Leadership

Stephen Williamson, MD, FACP


S Williamson Division Director, Hematology/Oncology
swilliamson@kumc.edu

Stephen Williamson, MD, FACP serves as the Division Director for the Department of Internal Medicine’s Division of Hematology/Oncology.  He is board certified in internal medicine and medical oncology and has extensive clinical trials expertise in gastrointestinal, lung and head and neck cancers. 

Dr. Williamson’s clinical interests include thoracic, head and neck and gastrointestinal cancer.  He currently serves as Medical Director of the University of Kansas Hospital’s Cancer Center and Medical Pavilion.   

Background

Dr. Williamson received his BS degree in Chemistry from Kansas Newman College in Wichita, KS.  He later received his Medical Degree from the University of Kansas School of Medicine in 1979.  Dr. Williamson completed his residency at the University of Oklahoma, Tulsa Medical College in Tulsa, Oklahoma.  In 1982 he went into private practice in internal medicine in Halstead, Kansas.  In 1983, he joined the Wichita Veterans Administration Medical Center as a staff physician.  He later completed his fellowship in medical oncology at the University of Kansas Medical Center.  Dr. Williamson joined the faculty of KUMC in 1986 as an Assistant Professor of Medicine.  He was appointed to Professor of Medicine in 1999 and named director of the Division of Hematology/Oncology in 2002.

Membership Organizations

  • American College of Physicians
  • American Society of Clinical Oncology
  • American Society of Internal Medicine
  • International Association for the Study of Lung Cancer

Recent Publications

  1. Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS:  Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer.  Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1402-10.
  2. Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP:  Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.  Ann Oncol 16(3):  425-429, 2005.
  3. Williamson SK, Crowley JJ, Lara PN, Tucker RW, Mc’Coy J, Lau DHM, Gandara DR: S0003: Paclitaxel/Carboplatin (PC) versus PC + Tirapazamine (PCT) in Advanced Non-Small Cell Lung Cancer (NSCLC). A Phase III Southwest Oncology Group (SWOG) Trial.  J Clin Oncol. 2005 Dec 20;23(36):9097-104
  4. Williamson SK, McCoy SA, Gandara DR, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Blanke CD, Abbruzzese JL:  Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer:  A Southwest Oncology Group Trial.  Am J Clin Oncol. 2006 Apr;29(2):116-22.
  5. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pederson J, Periman PO, Tanaka MS, Leichman CG, and Macdonald JS:  GI Intergroup 0144 - Phase III Trial Of 5-FU Based Chemotherapy Regimens Plus Radiotherapy In Postoperative Adjuvant Rectal Cancer.  J Clin Oncol:  24(22):3542-7, 2006.
  6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay, BP, Pitot, HC, Alberts, S: A Randomized Controlled Trial of Reduced Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin  and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial.  J Clin Oncol:  24(21):3347-53, 2006.
  7. Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH:  A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: southwest Oncology Group study 0007.  Cancer:  107(2):319-327, 2006.
  8. Baranda J and Williamson S:  The new paradigm in the treatment of colorectal cancer:  Are we hitting the right target?  Expert Opin. Invest. Drugs:  16(3):311-324, 2007.
  9. Ashley AC, Sargent DJ, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RD, Williamson SK, Findlay BP, Alberts SR, Pitot HC, Goldberg RM:  An updated efficacy and toxicity analysis of Intergroup trial N9741 in first line treatment of metastatic colorectal cancer with a focus on the patients treated with irinotecan and oxaliplatin (IROX)  Accepted for publication in Cancer, 2007.
  10. Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF:  Evaluation of the Combination of Docetaxel/Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Southwest Oncology Group Phase II Study.  Cancer Invest:  25(3):182-188, 2007.